Acasti Pharma Inc V.ACST

Primary Symbol: ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Successful Completion of its Merger with Grace Therapeutics

<< Previous

Bullboard Posts

Next >>

Comment by Canadian_101on Sep 01, 2021 4:22pm

171 Views

Post# 33795981

RE:RE:Successful Completion of its Merger with Grace Therapeutics

Games, games and more games, so glad I dumped this one and moved on.....

lscfa wrote: Acasti confirms that a reverse split of its common stock at an 8-1 ratio will be implemented to help regain compliance with NASDAQ minimum bid price rule,

<< Previous

Bullboard Posts

Next >>

Three point-of-sale stocks you should watch